These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 11895891)

  • 1. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical pharmacology of topoisomerase I inhibitors.
    Abang AM
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Jun; 4(3):152-67. PubMed ID: 11768329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
    De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
    Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Camptothecin and derivatives: a new class of antitumor agents].
    Torck M; Pinkas M
    J Pharm Belg; 1996; 51(4):200-7. PubMed ID: 8965250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel camptothecin derivatives.
    Legarza K; Yang LX
    In Vivo; 2005; 19(1):283-92. PubMed ID: 15796188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring.
    Beretta GL; Petrangolini G; De Cesare M; Pratesi G; Perego P; Tinelli S; Tortoreto M; Zucchetti M; Frapolli R; Bello E; Manzotti C; Fontana G; Bombardelli E; Battaglia A; Samorì C; Zunino F
    Cancer Res; 2006 Nov; 66(22):10976-82. PubMed ID: 17108136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK; Pawlik CA; Whipple DO; Wolverton JS
    Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity.
    Beretta GL; Zunino F
    Biochem Pharmacol; 2007 Nov; 74(10):1437-44. PubMed ID: 17540344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase I Inhibitors.
    Ewesuedo RB; Ratain MJ
    Oncologist; 1997; 2(6):359-364. PubMed ID: 10388070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
    Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance to topoisomerase I-targeting drugs.
    Rasheed ZA; Rubin EH
    Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments.
    Pantazis P
    Clin Cancer Res; 1995 Nov; 1(11):1235-44. PubMed ID: 9815917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
    Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase I interactive agents.
    Stewart CF
    Cancer Chemother Biol Response Modif; 2001; 19():85-128. PubMed ID: 11686040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase I interactive agents.
    Kirstein MN; Turner PK; Stewart CF
    Cancer Chemother Biol Response Modif; 2002; 20():99-123. PubMed ID: 12703202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.